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AngiogenesisAngiopoietin-1 (Ang1) and Ang2 are ligands for the receptor tyrosine kinase Tie2. Structural data suggest
that the two ligands bind Tie2 similarly. However, in endothelial cells Ang1 activates Tie2 whereas Ang2 can
act as an apparent antagonist. In addition, each ligand exhibits distinct kinetics of release following binding.
These observations suggest that additional factors inﬂuence function and binding of angiopoietins with
receptors in the cellular context. Previous work has shown that Ang1 binding and activation of Tie2 are
inhibited by Tie1, a related receptor that complexes with Tie2 in cells. In this study we have investigated
binding of Ang1 and Ang2 to Tie2 in endothelial cells. In contrast to Ang1, binding of Ang2 to Tie2 was found
to be not affected by Tie1. Neither PMA-induced Tie1 ectodomain cleavage nor suppression of Tie1
expression by siRNA affected the ability of Ang2 to bind Tie2. Analysis of the level of Tie1 co-
immunoprecipitating with angiopoietin-bound Tie2 demonstrated that Ang2 can bind Tie2 in Tie2:Tie1
complexes whereas Ang1 preferentially binds non-complexed Tie2. Stimulation of Tie1 ectodomain cleavage
did not increase the agonist activity of Ang2 for Tie2. Similarly, the Tie2-agonist activity of Ang2 was not
affected by siRNA suppression of Tie1 expression. Consistent with previous reports, loss of Tie1 ectodomain
enhanced the agonist activity of Ang1 for Tie2. Importantly, Ang2 was still able to antagonize the elevated
Ang1-activation of Tie2 that occurs on Tie1 ectodomain loss. Together these data demonstrate that Ang1 and
Ang2 bind differently to Tie2 at the cell surface and this is controlled by Tie1. This differential regulation of
angiopoietin binding allows control of Tie2 activation response to Ang1 without affecting Ang2 agonist
activity and maintains the ability of Ang2 to antagonize even the enhanced Ang1 activation of Tie2 that
occurs on loss of Tie1 ectodomain. This provides a mechanism by which signalling through Tie2 can be
modiﬁed by stimuli in the cellular microenvironment.: +44 116 252 3179.
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The receptor tyrosine kinase Tie2 is essential for vascular
development and maintenance and interacts with a family of ligands
known as the angiopoietins [1]. Signalling through Tie2 is tightly
controlled. The angiopoietin family contains members with full
agonist activity, the best characterized of which is Ang1, as well as,
unusually, members with low or partial activity, notably Ang2 [2,3].
This partial agonist activity of Ang2 allows the ligand to act as an
apparent antagonist to Ang1, by competing with Ang1 for Tie2
binding and thereby replacing the full agonist activity of Ang1 with
the much lower activity of Ang2 [2,3]. The activation state of Tie2 is
therefore determined by the relative balance between Ang1 and Ang2
[4].Ang1 and Ang2 have a similar overall structure, both are
glycoproteins of approximately 70 kDa in sizewith an amino-terminal
half comprising of coiled:coil domains important for ligand oligomer-
ization [4,5]. Downstream of this is a short linker sequence of
approximately 20 residues followed by a ﬁbrinogen related domain
(FReD). Binding of angiopoietins to Tie2 is mediated by the FReD [6,7].
This domain is found in a number of proteins and comprises of three
subdomains, designated A, B and P [8]. The P-domain mediates
interaction of FReD containing proteins such as ﬁbrinogen and
tachylectin 5A with their ligands and it is this region of the Ang
FReD that interacts with Tie2 [9]. The structure of Ang2 bound to Tie2
ectodomain has been solved and shows the Ang2 P-domain interact-
ing with the second Ig domain of the receptor which is within a
globular fold containing three Ig and three EGF-like domains at the
amino-terminal head of the receptor [9–11]. Comparison of un-
liganded and Ang2-bound Tie2 ectodomain suggests no signiﬁcant
conformational change in Tie2 on ligand binding [10]. Ang1 and Ang2
have approximately 73% amino acid identity in their P-domains. The
strong sequence similarity between Ang2 and Ang1 in the amino acid
528 T.M. Hansen et al. / Cellular Signalling 22 (2010) 527–532residues critical for Tie2 ectodomain interaction suggests that the two
ligands bind similarly with Tie2 under in vitro conditions with
puriﬁed proteins [9,10]. However, recent data indicate that interac-
tion of the ligands with their receptor on the cell surface may be more
complex. Following binding in endothelial cells Ang1 and Ang2 are
released prior to receptor internalization and the kinetics of release
are different for each ligand, with Ang2 release being more than
three-fold faster than Ang1 [2]. The mechanism responsible for this
differential behaviour of the ligands is not known.
In addition to its ligands, Tie2 physically interacts with the related
receptor tyrosine kinase Tie1 and the two receptors exist as pre-
formed hetero-oligomeric complexes at the endothelial surface
[12,13]. Tie1 ectodomain is not able to bind angiopoietins [5] and in
the Tie2:Tie1 complex it appears to partially occlude Ang1 binding to
Tie2 [14]. However, Tie1 ectodomain can undergo regulated cleavage
in which the extracellular domain of the receptor is removed by
metalloprotease activity in response to vascular endothelial growth
factor (VEGF), inﬂammatory stimuli, changes in shear stress and
stimulation of cells with phorbol esters [13,15–17]. This cleavage
removes Tie1 ectodomain from the Tie2:Tie1 complexes and releases
it as an intact fragment from the cell [15]. Regulated removal of Tie1
ectodomain increases access of Ang1 to Tie2 on the surface of
endothelial cells and enhances Ang1-activation of Tie2 and Tie2-
mediated signalling [14]. This provides a mechanism whereby
responsiveness of Tie2 to its activating ligand can be controlled by
VEGF and other stimuli.
Given the strong similarity between Ang1 and Ang2 in their Tie2-
binding domain it is possible that Ang2 binding to Tie2 is regulated by
Tie1 in the same way as occurs for Ang1. This would have important
consequences for the partial agonist activity of Ang2, allowing Tie1
ectodomain release to increase the number of Tie2 molecules able to
bind Ang2 and thereby increasing the net agonist activity of Ang2 on
the cell. The effects of Tie1 on Ang2 interaction with Tie2 have not yet
been deﬁned. In the present study, therefore, we investigate whether
Ang2 binding to Tie2 is inﬂuenced by Tie1 and compare interaction of
the two ligands with Tie2 in the Tie2:Tie1 complexes in endothelial
cells.
2. Materials and methods
2.1. Materials
Human umbilical vein endothelial cells (HUVEC) were obtained
from Promocell and were maintained in Medium 199 containing 20%
fetal calf serum, 5 units/ml heparin, and 50 µg/ml endothelial cell
growth supplement. Ang1 and Ang2 were obtained from R & D
Systems (Abingdon, UK). Antibodies recognizing Tie2 extracellular
domain were obtained from R & D Systems and those recognizing Tie1
and Tie2 intracellular domains and phosphotyrosine were from Santa
Cruz Biotechnology (from Autogen Bioclear, Calne, UK). Anti-His6
antibodies were from Sigma (Dorset, UK). Annealed, puriﬁed and de-
salted double-stranded siRNA oligonucleotides have been previously
detailed [18] and were obtained fromMWG Biotech (London, UK). All
other reagents were as previously described [14].
2.2. Cell treatments
Before the experiments cells were washed in PBS and incubated in
serum-free medium for 30 min. As appropriate, and indicated in
Results, cells were treated with the following concentrations of
reagents for the indicated times; PMA, 10 ng/ml, 30 min; TAPI-2,
100 μM, 2 h; Ang2, 200 ng/ml, 30 min and Ang1 200 ng/ml, 30 min,
unless otherwise indicated. In some experiments, indicated in Results,
HUVEC were transfected with control scrambled siRNA or siRNA
directed against Tie1 or Tie2. For transfection HUVEC were grown to
approximately 80% conﬂuence and then transfected with 100 nMsiRNA using Lipofectamine as directed in the manufacturer's protocol
24 h before treatments and cell lysis.
2.3. Immunoprecipitation and immunoblotting
Cells were washed with PBS and lysed with ice-cold lysis buffer
(50 mM Tris, pH 7.4, 50 mMNaCl, 1 mM sodium ﬂuoride, 1 mM EGTA,
1 mM sodium orthovanadate, 1% TritonX-100, complete protease
inhibitor mixture), cleared by centrifugation at 13,000×g for 5 min,
and assayed for protein content. In binding experiments, the cell-
impermeable cross-linker 3,3′-dithiobis(sulfosuccinimidylpropio-
nate) (DTSSP) was added to a ﬁnal concentration of 0.5 mM in PBS
for 30 min, cross-linking was terminated by addition of 20 mM Tris in
PBS followed by washing, and cell lysis.
For analysis of whole cell lysates, Laemmli sample buffer contain-
ing 100 mMdithiothreitol wasmixedwith cleared cellular lysates and
boiled for 5 min before loading equal amounts of protein onto SDS-
PAGE and resolving. For immunoprecipitates, supernatants cleared of
particulate material were immunoprecipitated by the addition of 2 µg
of the indicated antibody for 2–3 h in the presence of protein-A- or
protein-G-agarose. Immunoprecipitated proteins were recovered by
centrifugation at 13,000×g for 5 min and washed 3 times with wash
buffer (as lysis buffer but with 0.1% Triton X-100). Proteins were
eluted from beads by the addition of Laemmli sample buffer
containing 100 mM dithiothreitol and boiling for 5 min before SDS-
PAGE. For immunoblotting proteins were transferred to nitrocellulose
membranes electrophoretically and membranes probed with the
relevant antibodies. Immunoreactive proteins were visualized with
peroxidase-conjugated secondary antibodies and chemiluminescent
detection [19].
2.4. Data analysis
Bands on Western blots were quantiﬁed by densitometric
scanning of ﬁlms. Graphs were derived from 3 or more independent
experiments and data is plotted as means and standard error.
Statistical analysis was performed using Student's t test and
differences between means were judged statistically signiﬁcant for
pb0.05.
3. Results
3.1. Tie1 differentially regulates binding of Ang1 and Ang2 to Tie2
Tie1 regulates Ang1 signalling by limiting access of the ligand to its
receptor, Tie2, in the Tie1:Tie2 complexes found on the surface of
endothelial cells [14]. It is not known whether Tie1 also affects the
ability of the related ligand Ang2 to bind and activate Tie2. To begin
investigating this question we examined the effects of Tie1 ectodo-
main cleavage on interaction of Ang2 with Tie2 at the surface of
endothelial cells. As previously reported, addition of phorbol ester to
endothelial cells activates Tie1 ectodomain cleavage resulting in loss
of the extracellular domain. This effect has been well characterized
and is shown in Fig. 1A by the effects of PMA on loss of the upper band
of the 145 kDa doublet which corresponds to the surface expressed
full-length Tie1 [15]. Inclusion of the metalloproteinase inhibitor
TAPI-2 blocked Tie1 ectodomain cleavage (Fig. 1A). To examine the
effect of Tie1 cleavage on Ang2 binding endothelial cells were treated
with control vehicle, PMA, or PMA plus TAPI-2 before addition of His6-
tagged Ang2, followed by cross-linking and recovery of Ang2 together
with its bound receptor by immunoprecipitation with anti-His6
antibodies (Fig. 1A). As expected, immunoprecipitation in the absence
of His6-tagged Ang2 did not recover any Tie2. However, in the
presence of Ang2 immunoprecipitation resulted in recovery of bound
Tie2, conﬁrming interaction between Ang2 and its receptor on
endothelial cells (Fig. 1A, B). Induction of Tie1 cleavage by PMA did
Fig. 1. Binding between Ang2 and Tie2 is not regulated by Tie1 ectodomain cleavage.
(A) Endothelial cells were treated with 10 ng/ml PMA or PMA plus 100 μM TAPI-2
before addition of 200 ng/ml Ang2 for 30 min, as indicated, followed by cross-linking
with the cell-impermeable cross-linker DTSSP. 20 mM Tris was added to quench cross-
linking before washing and cell lysis. Ang2 was immunoprecipitated via its His-tag and
immunoprecipitates or whole cell lysates (Wcl) were resolved by SDS/PAGE. Tie2
bound to Ang2 and Tie1 and Tie2 in whole cell lysates were detected by
immunoblotting as indicated. Tie1 ectodomain cleavage is indicated by loss of the
higher molecular mass Tie1 immunoreactive band corresponding to surface expressed
Tie1 (arrow). (B) Tie2 bound to Ang2 was determined by immunoblotting in three
independent experiments. Data is presented as means and SEM. No signiﬁcant effect of
PMA on Tie2 binding was observed (Student's t test).
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presence of TAPI-2 (Fig. 1A). Quantitation of the amounts of Tie2
bound to Ang2 was performed in three independent experiments by
densitometric scanning of blots, this conﬁrmed no statistically
signiﬁcant change in Ang2 binding to Tie2 in response to PMA
activated Tie1 cleavage (Fig. 1B).
The effects of Tie1 on binding of Ang2 to Tie2 were explored
further using an siRNA approach to generate endothelial cells lacking
Tie1. Cells were transfected with control siRNA or siRNA directed
against Tie1 and expression of Tie1 determined by immunoblotting.
Tie1 siRNA effectively suppressed Tie1 expression (Fig. 2A). Interac-
tion of Ang2 with Tie2 in endothelial cells expressing Tie1, and in
which Tie1 expression was inhibited by siRNA, was determined by
addition of the ligand and immunoprecipitation as before. Ang2 was
able to bind Tie2 equally well in the absence and presence of Tie1
(Fig. 2A). The different effects of Tie1 on interaction of Ang1 and Ang2
with Tie2 were directly compared by examining the ability of Ang1
and Ang2 to bind and recover Tie2 from control cells and cells lacking
Tie1. Loss of Tie1 did not affect the binding of Ang2 to Tie2, however,
binding of Ang1 to Tie2 was increased in the absence of Tie1 (Fig. 2B).
3.2. Ang1 preferentially binds free Tie2
As Ang1 binds better to Tie2 in the absence of Tie1, and Ang2 binds
equally well to Tie2 irrespective of Tie1, we hypothesised that Ang2
can bind Tie2 in the Tie1:Tie2 complex whereas Ang1 preferentially
binds to non-complexed Tie2. To test this we examined the ability ofAng1 and Ang2 to bind and recover Tie2 and Tie1:Tie2 complexes. It
has previously been reported [4] and we have conﬁrmed (data not
shown) that Ang2 does not bind to Tie1 ectodomain directly. As
shown in Fig. 3, Ang2 immunoprecipitates contain both Tie2 and Tie1.
However, in cells lacking Tie2, as a result of suppression of Tie2
expression by siRNA, Ang2 is unable to recover Tie1 (Fig. 3A)
consistent with the inability of Ang2 to bind directly to Tie1 but to
bind Tie2 in the Tie1:Tie2 complex. The binding of Ang1 and Ang2 to
the Tie1:Tie2 complex was tested by examining recovery of Tie1 and
Tie2 by each of the ligands. Tie2 bound to Ang2 had approximately
two-fold more Tie1 associated with it than the Tie2 bound to Ang1
(Fig. 3B). These ﬁndings are consistent with the preferential binding
of Ang1 to Tie2 in the absence of Tie1 and suggest that Ang1
preferentially binds a free or Tie1-poor pool of Tie2.
3.3. Effects of Tie1 on ability of Ang1 and Ang2 to activate Tie2
The reason why Ang2 is a partial rather than full agonist is not
known. It is possible that Tie1 could suppress full agonist activity of
Ang2. Therefore to examine the inﬂuence of Tie1 ectodomain and full-
length Tie1 on the agonist activity of Ang2 we examined the effects of
Tie1 ectodomain cleavage on the ability of Ang2 to activate Tie2
phosphorylation. Endothelial cells were treated with Ang2 in the
presence or absence of PMA and phosphorylated Tie2 immunopreci-
pitated. Ang2 induced only a marginal increase in the amount of Tie2
immunoprecipitated by anti-phosphotyrosine antibodies demon-
strating a mild agonist activity. However, induction of Tie1 ectodo-
main cleavage did not increase the ability of Ang2 to activate Tie2
(Fig. 4A). The impact of Tie1 on Ang2 activation of Tie2 was further
examined by suppression of Tie1 expression using siRNA. Endothelial
cells transfected with siRNA directed against Tie1 expressed unde-
tectable levels of this receptor (Fig. 4B). Again, Ang2 exhibited very
low agonist activity and this was not increased by removal of Tie1
(Fig. 4B). These data demonstrate that Tie1 does not affect the agonist
activity of Ang2.
Our data demonstrates that Tie1 does not affect Ang2 access to
Tie2 or the partial agonist activity of Ang2, in contrast to the situation
for Ang1 where Tie1 loss increases the number of Tie2 receptors
accessed by Ang1 and therefore activated by Ang1 [14]. As Ang2 is
able to bind Tie2 irrespective of the presence of Tie1 ectodomain it
would be expected that Ang2 would still be able to act as an apparent
antagonist of Ang1 on Tie2 receptors made newly available to it by
loss of Tie1.We directly tested the apparent antagonist effects of Ang2
on Ang1 activity in the presence and absence of Tie1 ectodomain. To
do this, endothelial cells were treated with control or PMA before
being activated with Ang1 in the presence or absence of Ang2 and the
net effect on Tie2 activation determined. As previously described,
Ang1 activated Tie2 and this was antagonized by Ang2 (Fig. 5).
Induction of Tie1 cleavage by addition of PMA caused an increase in
Tie2 activation by Ang1 however even under these conditions Ang2
was still able to antagonize Ang1-activation of Tie2 (Fig. 5).
4. Discussion
In this study we demonstrate that Ang1 and Ang2 interact
differently with Tie2 on endothelial cells. Ang2 binding to Tie2 is
not affected by the presence of Tie1 and neither Tie1 ectodomain
cleavage nor suppression of Tie1 expression inﬂuence Ang2 binding.
This contrasts with the situation for Ang1 where binding to Tie2 is
regulated by the presence of Tie1 ectodomain, and cleavage of Tie1 or
suppression of Tie1 expression increases Ang1 binding to Tie2 and the
ability of the ligand to activate the receptor [14,20]. Our data also
demonstrate that Ang1 binds preferentially to Tie2 that is either not
complexed to Tie1 or in Tie1-poor complexes, consistent with lower
binding in the presence of Tie1 ectodomain. Loss of Tie1 ectodomain
occurs in vivo and is activated by VEGF, inﬂammatory stimuli and
Fig. 2. Suppression of Tie1 expression differentially affects binding of Ang1 and Ang2 to Tie2 in endothelial cells. (A) Endothelial cells were transfected with siRNA directed against
Tie1 or control randomised siRNA (Sc) and cultured for 24 h before addition of control vehicle (C) or 200 ng/ml Ang2 (A2) for 30 min as indicated followed by cross-linking with the
cell-impermeable cross-linker DTSSP. 20 mM Tris was added to quench cross-linking before washing and cell lysis. Ang2 was immunoprecipitated and immunoprecipitates or whole
cell lysates (Wcl) were resolved by SDS/PAGE. Tie2 bound to Ang2 and Tie1 and Tie2 in whole cell lysates were detected by immunoblotting as indicated. (B) Endothelial cells were
transfected with siRNA directed against Tie1 or control randomised siRNA (Sc) and cultured for 24 h before addition of 200 ng/ml Ang1 (A1) or Ang2 (A2) for 30 min as indicated.
Cross-linking, quenching and immunoprecipitation were performed as above and Tie2 bound to Ang1 and Ang2 and Tie1 and Tie2 in whole cell lysates were detected by
immunoblotting as indicated. The effect of suppression of Tie1 expression by siRNA on Ang1 and Ang2 binding to Tie2 on cells was determined in three independent experiments by
immunoblotting and densitometric quantiﬁcation of blots. Data are presented asmeans and SEM. ⁎ indicates Ang1 binding to Tie2 was signiﬁcantly increased by loss of Tie1 (pb0.05,
Student's t test).
530 T.M. Hansen et al. / Cellular Signalling 22 (2010) 527–532changes in shear stress over a period of minutes [13,16]. The effect of
Tie1 ectodomain on Ang binding to Tie2, therefore, provides a
mechanism for acute regulation and integration of Ang signalling
with that of other signalling inputs to the cell at the level of the Tie2
receptor, with enhanced Ang1 signalling being favoured in endothe-
lial cells experiencing increased VEGF or receiving inﬂammatory or
shear stimuli. In addition, it would be expected that over the longer
term factors altering the expression level of Tie1 and Tie2:Tie1 ratio in
the cell would also be expected to modify the endothelial response to
Ang1.
The crystal structure of Ang2 bound to Tie2 ectodomain has been
solved and reveals the Tie2 ectodomain to exist as a globular head
comprising of three Ig and three EGF-like domains followed by a rod-
like structure incorporating the three FnIII motifs [9–11]. Ang2
binding occurs at the second of the amino-terminal Ig domains and
does not appear to induce any signiﬁcant conformational change in
either receptor ectodomain or ligand [10]. It is the most carboxy-
terminal domain in Ang2, the P-domain, that binds Tie2 [9–11]. Based
on the structural determinations and sequence similarities it is highly
likely that all the angiopoietins bind in a structurally similar manner
to Tie2 [10]. Our data indicates that in the cellular context Tie1
ectodomain can modify this interaction differentially between Ang1and Ang2. It will be important to gain structural details of how Tie1
complexed with Tie2 differentially modiﬁes this binding.
The present study has focussed on the impact of Tie1 ectodomain
on the ability of Ang1 and Ang2 to interact with Tie2. In addition to
affecting Ang1 binding, it is possible that Tie1 could also have other
effects on Tie2 signalling, for example Tie1 intracellular domain may
inﬂuence the proﬁle of sites phosphorylated on Tie2 intracellular
domain and thus modify downstream signalling pathways. Further
workwill be required to examine such potential effects of Tie1 on Tie2
intracellular domain phosphorylation proﬁle and recruitment of
signalling intermediates.
Ang1 is an agonist in endothelial cells whereas Ang2 can act as an
antagonist or partial agonist. The ﬁnding that Ang1 and Ang2 interact
differently with Tie2 on the endothelium and that this is differentially
regulated by Tie1 suggested that Tie1 may have a role in determining
the agonist status of each ligand. We hypothesised that the lack of full
agonist activity of Ang2 was due to Tie1. To test this we examined the
effects of Ang2 on Tie2 activation in cells in which Tie1 ectodomain
cleavage had occurred and also in cells in which expression of Tie1
was suppressed by siRNA. Contrary to our hypothesis we found that
neither Tie ectodomain cleavage nor lack of Tie1 inﬂuenced the ability
of Ang2 to activate Tie2 phosphorylation. These data demonstrate that
Fig. 3. Ang1andAng2binddifferentially toTie2 inTie2:Tie1 complexes. (A)Endothelial cells
were transfected with siRNA directed against Tie2 or control randomised siRNA (Sc) and
cultured for 24 h before addition of 200 ng/ml Ang2 for 30 min followed by cross-linking
with the cell-impermeable cross-linker DTSSP. 20 mM Tris was added to quench cross-
linking before washing and cell lysis. Ang2 was immunoprecipitated and immunoprecipi-
tates or whole cell lysates (Wcl) were resolved by SDS/PAGE. Tie1 and Tie2 recovered from
immunoprecipitates and in whole cell lysates were detected by immunoblotting as
indicated. (B) Endothelial cells were treated with 200 ng/ml Ang1 or 200 ng/ml Ang2 for
30 min before cross-linking, quenching and immunoprecipitation, as above, and Tie1 and
Tie2 recovered from immunoprecipitates were detected by immunoblotting as indicated.
Tie1 and Tie2 bound to angiopoietins were determined by immunoblotting in three
independent experiments. Data is presented as means and SEM of the ratio of Tie1:Tie2
recovered. ⁎ indicates statistically signiﬁcant difference between Tie1:Tie2 ratio recovered
by Ang1 and Ang2 (pb0.05, Student's t test).
Fig. 4. Tie1does not affect the agonist activity of Ang2. (A) Endothelial cellswere treatedwith con
were lysedand immunoprecipitatedwithanti-phosphotyrosine antibodies (Py-IP). Tie2 in immun
following SDS/PAGE. Tie1 ectodomain cleavage is indicatedby loss of thehighermolecularmass Ti
on Ang2-induced Tie2 phosphorylation was determined in three independent experiments by im
SEM. ⁎ indicates Ang2 signiﬁcantly increased Tie2 phosphorylation (pb0.05, Student's t test). (B)
siRNA (Sc) and cultured for 24 h before addition of 200 ng/ml Ang2 for 30 min. Cells were lyse
immunoprecipitates andTie2andTie1 inwhole cell lysates (Wcl)weredetectedby immunoblottin
Tie2phosphorylationwas determined in three independent experiments by immunoblotting and
signiﬁcantly increased Tie2 phosphorylation compared with control Sc Si transfected cells (pb0.
531T.M. Hansen et al. / Cellular Signalling 22 (2010) 527–532the presence of Tie1 is not the sole determinant of Ang2 agonist
activity. The ability of Ang2 to bind Tie2 in Tie2:Tie1 complexes raises
the possibility that Ang2 antagonizes Ang1 by favouring Tie2:Tie1
complex formation and thereby inhibiting access of Ang1 to Tie2.
However, the ﬁnding that Ang2 can still suppress Ang1-activation of
Tie2 even when Tie1 ectodomain is cleaved, and therefore unable to
restrict Ang1 access (Fig. 5), indicates Ang2 can act as a direct Ang1
antagonist without involvement of the Tie1 ectodomain.
The differential binding of Ang1 and Ang2 to Tie2 has important
consequences for regulation of Tie2 responsiveness and signalling. If
Tie1 did restrict Ang2 binding, as it does for Ang1, then in the presence
of Ang2, or a high Ang2/Ang1 ratio, Tie1 cleavage would lead to an
increase in the number of Tie2 receptors binding Ang2. As Ang2 is a
partial agonist for Tie2 [2,3] this would increase the number of
partially activated Tie2 receptors in each cell causing a net increase in
Ang2 agonist activity. In this case Tie1 cleavage would increase both
Ang1-mediated Tie2 activation and Ang2-mediated Tie2 activation.
However, Ang1 and Ang2were found to bind differently and Tie1 does
not affect Ang2 binding or total number of Tie2 receptors (partially)
activated by Ang2. This therefore allows an increase in total Tie2
signalling at high Ang1/Ang2 ratios but retains the apparent
inhibitory effect of Ang2 as the ratio shifts towards lower Ang1/Ang2.
Recently it has been suggested that Ang1 and Ang2 interaction
with the cell surface is more complicated than that of many ligand:
receptor interactions and that the two ligands interact differently
with receptors on the endothelial plasma membrane, as evidenced by
their release following initial binding and the more rapid release of
Ang2 than Ang1 [2]. Our data supports this assertion of differentialtrol vehicle or 10 ng/ml PMAbefore addition of 200 ng/mlAng2 for 30 min as indicated. Cells
oprecipitates andTie2andTie1 inwhole cell lysates (Wcl)weredetectedby immunoblotting
e1 immunoreactive band corresponding to surface expressedTie1 (arrow). Theeffect of PMA
munoblotting and densitometric quantiﬁcation of blots. Data are presented as means and
Endothelial cells were transfected with siRNA directed against Tie1 or control randomised
d and immunoprecipitated with anti-phosphotyrosine antibodies (Py-IP). Tie2 detected in
g followingSDS/PAGE.Theeffect of control andTie1 siRNAon theabilityofAng2 to stimulate
densitometric quantiﬁcationof blots. Data are presented asmeans and SEM. ⁎ indicates Ang2
05, Student's t test), however loss of Tie1 did not enhance Ang2-activation of Tie2.
Fig. 5. Ang2 inhibits enhancedAng1-activation of Tie2. Endothelial cellswere treatedwith
control vehicle or 10 ng/ml PMA before addition of 50 ng/ml Ang1 in the absence and
presence of 1000 ng/ml Ang2 for 30 min as indicated. Cells were lysed and immunopre-
cipitated with anti-Tie2 antibodies. Phosphorylated Tie2 (pTie2) was detected by
immunoblotting with anti-phosphotyrosine antibodies following SDS/PAGE. Blots were
strippedand re-probedwith anti-Tie2 antibodies. Tie2phosphorylationwasdetermined in
three independent experiments. Data is presented as means and SEM of pTie2/Tie2 ratio
normalized to that of PMA plus Ang1. ⁎ indicates statistically signiﬁcant difference
between control and Ang1 stimulated cells, † indicates signiﬁcant inhibition of Ang1
induced phosphorylation by Ang2 and # indicates signiﬁcant enhancement of Ang1-
induced phosphorylation by PMA (pb0.05, Student's t test).
532 T.M. Hansen et al. / Cellular Signalling 22 (2010) 527–532and complex binding at the cell surface and implicates Tie1 as a
differential regulator, though not direct binder, of the ligands. It is
clear that the angiopoietin signalling mechanisms are multifaceted
and likely to involve other regulatory inﬂuences in addition to the
mechanism of differential regulation of Ang responsiveness via Tie1.
The angiopoietins have key roles in development and maintenance of
the vascular system. It is important, therefore, to elucidate how
signalling by these ligands is controlled both to provide new insight
into general principles of signal integration and regulation, as well as
to improve understanding of how the angiopoietins contribute to
vascular maintenance and disease.
The ability of cells to integrate multiple signalling inputs and
transduce these into appropriate functional responses is essential for
normal development and homeostasis. Integration and cross-talk
between signalling pathways occur at intracellular nodes where
different signalling cascades intersect [21], but can also arise at the
level of receptor activation. For example in the endothelium, the
Notch signalling pathway regulates responsiveness to VEGF, at least
partly by modifying expression of soluble- and full-length-VEGFR1
which binds VEGF preventing its interaction and activation of VEGFR2
and inhibiting downstream signalling [22,23]. This cross-talk between
Notch and VEGF signalling is important in maintaining the distinctionbetween leading tip cells and trailing stalk cells during angiogenesis
and without this normal vessel formation is disrupted [24]. In the case
of the receptor tyrosine kinase Tie2, signalling is tightly controlled by
the balance of Ang1:Ang2. We suggest it is also regulated by Tie1
ectodomain, which itself is acutely controlled by stimuli distinct from
angiopoietins including VEGF and changes in shear stress. The result
of the differential effects of Tie1 on binding of Ang1 and Ang2 to Tie2
shown in this study is that stimuli modulating Tie1 cleavage control
the amplitude of the Tie2 response to Ang1 without increasing the net
Ang2 agonist activity and maintaining the ability of Ang2 to
antagonize Ang1. The combination Ang1:Ang2 ratio, Tie1:Tie2
balance and Tie1 cleavage status provide a complex multilayered
control over signalling through Tie2 that can determine the Tie2
signal in response to its ligands in the context of the ambient
angiogenic, inﬂammatory and shear status of the cellular
environment.
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